Literature DB >> 23602444

Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors.

Amir Nasrolahi Shirazi1, Rakesh Kumar Tiwari, Alex Brown, Dindyal Mandal, Gongqin Sun, Keykavous Parang.   

Abstract

A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC50=2.8 μM) than C[KW]5, L(KW)5, C[RW]4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 μM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be 0.8 μM in a radioactive assay using [γ-(32)P]-ATP and polyE4Y as the substrate. C[RW]5 was a noncompetitive Src kinase inhibitor, showing approximately fourfold more selectivity towards Src than Abl.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602444      PMCID: PMC3660729          DOI: 10.1016/j.bmcl.2013.03.124

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.

Authors:  S Schenone; O Bruno; A Ranise; F Bondavalli; C Brullo; P Fossa; L Mosti; G Menozzi; F Carraro; A Naldini; C Bernini; F Manetti; M Botta
Journal:  Bioorg Med Chem Lett       Date:  2004-05-17       Impact factor: 2.823

2.  Identification of N-terminal lobe motifs that determine the kinase activity of the catalytic domains and regulatory strategies of Src and Csk protein tyrosine kinases.

Authors:  Kezhen Huang; Yue-Hao Wang; Alex Brown; Gongqin Sun
Journal:  J Mol Biol       Date:  2009-03-06       Impact factor: 5.469

3.  Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7.

Authors:  Stephanie C Pero; Lyn Oligino; Roger J Daly; Amy L Soden; Chen Liu; Peter P Roller; Peng Li; David N Krag
Journal:  J Biol Chem       Date:  2002-01-24       Impact factor: 5.157

4.  Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters.

Authors:  Deendayal Mandal; Amir Nasrolahi Shirazi; Keykavous Parang
Journal:  Angew Chem Int Ed Engl       Date:  2011-09-15       Impact factor: 15.336

5.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival.

Authors:  A P Belsches-Jablonski; J S Biscardi; D R Peavy; D A Tice; D A Romney; S J Parsons
Journal:  Oncogene       Date:  2001-03-22       Impact factor: 9.867

6.  Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach.

Authors:  J R Kamath; R Liu; A M Enstrom; Q Lou; K S Lam
Journal:  J Pept Res       Date:  2003-12

7.  Activity of pp60c-src in 60 different cell lines derived from human tumors.

Authors:  R J Budde; S Ke; V A Levin
Journal:  Cancer Biochem Biophys       Date:  1994-10

8.  Use of synthetic peptides and copolymers to study the substrate specificity and inhibition of the protein tyrosine kinase pp60c-src.

Authors:  R J Budde; N U Obeyesekere; S Ke; J S McMurray
Journal:  Biochim Biophys Acta       Date:  1995-04-05

Review 9.  SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Authors:  Markus Warmuth; Robert Damoiseaux; Yi Liu; Doriano Fabbro; Nathanael Gray
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

10.  Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.

Authors:  Nguyen-Hai Nam; Guofeng Ye; Gongqin Sun; Keykavous Parang
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

View more
  8 in total

1.  Surface decorated gold nanoparticles by linear and cyclic peptides as molecular transporters.

Authors:  Amir Nasrolahi Shirazi; Rakesh Kumar Tiwari; Donghoon Oh; Brian Sullivan; Kellen McCaffrey; Dindyal Mandal; Keykavous Parang
Journal:  Mol Pharm       Date:  2013-07-25       Impact factor: 4.939

Review 2.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

3.  Synthesis of 4-aryl-6-indolylpyridine-3-carbonitriles and evaluation of their antiproliferative activity.

Authors:  Naglaa Salem El-Sayed; Amir Nasrolahi Shirazi; Magda Goda El-Meligy; Ahmed Kamel El-Ziaty; Zenat Adeeb Nagib; Keykavous Parang
Journal:  Tetrahedron Lett       Date:  2014-02-05       Impact factor: 2.415

4.  Understanding Cell Penetration of Cyclic Peptides.

Authors:  Patrick G Dougherty; Ashweta Sahni; Dehua Pei
Journal:  Chem Rev       Date:  2019-05-14       Impact factor: 60.622

5.  Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters.

Authors:  Amir Nasrolahi Shirazi; Donghoon Oh; Rakesh Kumar Tiwari; Brian Sullivan; Anju Gupta; Geoffrey D Bothun; Keykavous Parang
Journal:  Mol Pharm       Date:  2013-11-12       Impact factor: 4.939

6.  Cyclic Peptides as Protein Kinase Inhibitors: Structure-Activity Relationship and Molecular Modeling.

Authors:  Michel F Sanner; Khalid Zoghebi; Samara Hanna; Saghar Mozaffari; Simin Rahighi; Rakesh K Tiwari; Keykavous Parang
Journal:  J Chem Inf Model       Date:  2021-05-17       Impact factor: 6.162

7.  Cyclic peptide-selenium nanoparticles as drug transporters.

Authors:  Amir Nasrolahi Shirazi; Rakesh K Tiwari; Donghoon Oh; Brian Sullivan; Anil Kumar; Yousef A Beni; Keykavous Parang
Journal:  Mol Pharm       Date:  2014-09-17       Impact factor: 4.939

8.  Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase.

Authors:  Farial Tavakoli; Mohamad Reza Ganjalikhany
Journal:  PLoS One       Date:  2019-05-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.